BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34697402)

  • 1. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective.
    Pokrzywinski R; Hareendran A; Nalysnyk L; Cowie S; Crowe J; Hopkin J; Joshi D; Pulikottil-Jacob R
    Sci Rep; 2021 Oct; 11(1):20972. PubMed ID: 34697402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD).
    McGovern MM; Avetisyan R; Sanson BJ; Lidove O
    Orphanet J Rare Dis; 2017 Feb; 12(1):41. PubMed ID: 28228103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life impacts of olipudase alfa: The experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency.
    Raebel EM; Wiseman S; Donnelly C; Mathieson T; Pountney J; Crowe J; Hopkin J
    Orphanet J Rare Dis; 2024 Feb; 19(1):36. PubMed ID: 38303068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health insurance literacy and health services access barriers in Niemann-Pick disease: the patient and caregiver voice.
    Diaz GA; Crowe J; Hopkin J
    Orphanet J Rare Dis; 2022 Sep; 17(1):332. PubMed ID: 36056366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): Literature review and report of new cases.
    Cassiman D; Packman S; Bembi B; Turkia HB; Al-Sayed M; Schiff M; Imrie J; Mabe P; Takahashi T; Mengel KE; Giugliani R; Cox GF
    Mol Genet Metab; 2016 Jul; 118(3):206-213. PubMed ID: 27198631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.
    Pulikottil-Jacob R; Ganz ML; Fournier M; Petruski-Ivleva N
    Adv Ther; 2023 May; 40(5):2234-2248. PubMed ID: 36897522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Potential Symptoms and Risks Associated with Acid Sphingomyelinase Deficiency on Patients and Caregivers: A Best-Worst Scaling Study.
    Mansfield C; Nalysnyk L; Joshi D; Coulter J; Pulikottil-Jacob R
    Patient Prefer Adherence; 2023; 17():927-939. PubMed ID: 37020662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.
    McGovern MM; Wasserstein MP; Bembi B; Giugliani R; Mengel KE; Vanier MT; Zhang Q; Peterschmitt MJ
    Orphanet J Rare Dis; 2021 May; 16(1):212. PubMed ID: 33971920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in Germany.
    Mengel E; Muschol N; Weinhold N; Ziagaki A; Neugebauer J; Antoni B; Langer L; Gasparic M; Guillonneau S; Fournier M; Laredo F; Pulikottil-Jacob R
    Orphanet J Rare Dis; 2024 Apr; 19(1):161. PubMed ID: 38615062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): Exploring the potential indicators of diagnosis using quantitative and qualitative data.
    Doerr A; Farooq M; Faulkner C; Gould R; Perry K; Pulikottil-Jacob R; Rajasekhar P
    Mol Genet Metab Rep; 2024 Mar; 38():101052. PubMed ID: 38469089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus.
    Scarpa M; Barbato A; Bisconti A; Burlina A; Concolino D; Deodato F; Di Rocco M; Dionisi-Vici C; Donati MA; Fecarotta S; Fiumara A; Galeone C; Giona F; Giuffrida G; Manna R; Mariani P; Pession A; Scopinaro A; Spada M; Spandonaro F; Trifirò G; Carubbi F; Cappellini MD
    Intern Emerg Med; 2023 Apr; 18(3):831-842. PubMed ID: 36882619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy.
    Jones SA; McGovern M; Lidove O; Giugliani R; Mistry PK; Dionisi-Vici C; Munoz-Rojas MV; Nalysnyk L; Schecter AD; Wasserstein M
    Mol Genet Metab; 2020; 131(1-2):116-123. PubMed ID: 32616389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B).
    Geberhiwot T; Wasserstein M; Wanninayake S; Bolton SC; Dardis A; Lehman A; Lidove O; Dawson C; Giugliani R; Imrie J; Hopkin J; Green J; de Vicente Corbeira D; Madathil S; Mengel E; Ezgü F; Pettazzoni M; Sjouke B; Hollak C; Vanier MT; McGovern M; Schuchman E
    Orphanet J Rare Dis; 2023 Apr; 18(1):85. PubMed ID: 37069638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up.
    Lipiński P; Kuchar L; Zakharova EY; Baydakova GV; Ługowska A; Tylki-Szymańska A
    Orphanet J Rare Dis; 2019 Feb; 14(1):55. PubMed ID: 30795770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: A retrospective chart review study.
    Pulikottil-Jacob R; Dehipawala S; Smith B; Athavale A; Gusto G; Chandak A; Khachatryan A; Banon T; Fournier M; Guillonneau S; Pollissard L; Munoz-Rojas MV
    Mol Genet Metab Rep; 2024 Mar; 38():101040. PubMed ID: 38188692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts and Burden of Niemann pick Type-C: a patient and caregiver perspective.
    Mengel E; Patterson MC; Chladek M; Guldberg C; Í Dali C; Symonds T; Lloyd-Price L; Mathieson T; Crowe J; Burbridge C
    Orphanet J Rare Dis; 2021 Nov; 16(1):493. PubMed ID: 34819124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).
    Wasserstein M; Dionisi-Vici C; Giugliani R; Hwu WL; Lidove O; Lukacs Z; Mengel E; Mistry PK; Schuchman EH; McGovern M
    Mol Genet Metab; 2019 Feb; 126(2):98-105. PubMed ID: 30514648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein non-metastatic protein B (GPNMB) plasma values in patients with chronic visceral acid sphingomyelinase deficiency.
    Eskes ECB; van der Lienden MJC; Sjouke B; van Vliet L; Brands MMMG; Hollak CEM; Aerts JMFG
    Mol Genet Metab; 2023 Aug; 139(4):107631. PubMed ID: 37453187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: A retrospective multicentric study of 28 adult cases].
    Lidove O; Belmatoug N; Froissart R; Lavigne C; Durieu I; Mazodier K; Serratrice C; Douillard C; Goizet C; Cathebras P; Besson G; Amoura Z; Tazi A; Gatfossé M; Rivière S; Sené T; Vanier MT; Ziza JM
    Rev Med Interne; 2017 May; 38(5):291-299. PubMed ID: 27884455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic lipid profile in patients with Niemann-Pick disease type B: What treatment strategies?
    Maines E; Franceschi R; Rizzardi C; Deodato F; Piccoli G; Gragnaniello V; Burlina A; Soffiati M
    J Clin Lipidol; 2022; 16(2):143-154. PubMed ID: 35181260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.